Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia
about
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axisActivation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin geneDopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropesGAP1(IP4BP)/RASA3 mediates Galphai-induced inhibition of mitogen-activated protein kinase.Molecular interaction of BMP-4, TGF-beta, and estrogens in lactotrophs: impact on the PRL promoter.Prolactin induces apoptosis of lactotropes in female rodents.Enhanced hypothalamic leptin signaling in mice lacking dopamine D2 receptors.Alteration in G proteins and prolactin levels in pituitary after ethanol and estrogen treatment.Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor.Genesis of prolactinomas: studies using estrogen-treated animalsDopamine modulates cell cycle in the lateral ganglionic eminence.Ethanol alters production and secretion of estrogen-regulated growth factors that control prolactin-secreting tumors in the pituitaryDistinct roles for Galpha(i)2 and Gbetagamma in signaling to DNA synthesis and Galpha(i)3 in cellular transformation by dopamine D2S receptor activation in BALB/c 3T3 cells.GH Dysfunction in Engrailed-2 Knockout Mice, a Model for Autism Spectrum Disorders.Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs.Roles of dopamine 2 receptor isoforms and g proteins in ethanol regulated prolactin synthesis and lactotropic cell proliferation.Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.What can we learn from rodents about prolactin in humans?Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.Pituitary volume in psychosis: the first review of the evidence.Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites.Regulatory roles of heterogeneous nuclear ribonucleoprotein M and Nova-1 protein in alternative splicing of dopamine D2 receptor pre-mRNA.PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.Fetal Alcohol Exposure Reduces Dopamine Receptor D2 and Increases Pituitary Weight and Prolactin Production via Epigenetic Mechanisms.Neuroendocrine regulation of prolactin secretion during late pregnancy: easing the transition into lactation.Galanin regulates prolactin release and lactotroph proliferation.Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family.Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia.Molecular physiology of pituitary development: signaling and transcriptional networks.Anatomical profiling of G protein-coupled receptor expressionThe role of dopamine signaling in epileptogenesis.Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomasPharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.A Comparative Study of Pituitary Volume Variations in MRI in Acute Onset of Psychiatric Conditions.Risk assessments for chronic exposure of children and prospective parents to ethylbenzene (CAS No. 100-41-4).Differential signaling of dopamine-D2S and -D2L receptors to inhibit ERK1/2 phosphorylation.A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism.Targeted disruption of the murine galanin gene.
P2860
Q26772167-7BC1E97D-2631-4F06-A793-E47A560BDC4CQ28087609-334D7CD5-A069-4A45-B1A6-787360FC0FEFQ28571661-B019C3C3-DB41-46DC-BAD4-5E76315B3492Q28580699-86566813-C9EB-4631-A5A9-AB3DE33943FCQ33379513-D133304B-0522-418B-B957-BB2AA49A4311Q33642161-F433B79C-3882-47B1-81D2-72C8BC39C951Q33654808-9A76CBB5-CEF5-4F56-B98D-0E54C01F84F1Q33726520-5F4C3C8B-5390-4282-9111-F9BF337C506BQ33849218-F763FA46-62A6-4871-B904-35CEBA9CCD11Q33862807-7117037F-F58A-4641-8675-D920F97D3076Q33899741-67FBCD23-2DD4-433A-BD12-8A5EC98C4CEEQ33947268-67F14041-D692-4505-8138-7277E9229AECQ33954415-B3098C29-D802-426E-A922-F647DCC4AE4EQ33962164-326A3A60-A2CB-4225-914F-08C9C96DD043Q34113308-81C36662-A017-43DA-BF2A-07DF2AED1861Q34394799-00B8C490-7998-4359-8F18-063582853662Q34429544-DC2E4F47-8B50-4990-B25C-92DB6284D849Q34529081-D0F1FB08-4B2C-4CF3-8064-B3866FCC517AQ34721567-61DA95D7-4EAE-4332-B2FA-6E2C6221E6E4Q34798387-CA5F1944-1F86-4BE0-A8CF-2C8CC6D05587Q34809978-487968BC-05D9-459B-8C3A-155ABBC89206Q34923951-AB4D18D2-AA2D-46FA-B7CB-B300BAC13D7DQ35107580-E6D7F1AB-5DC2-4013-900A-C112491BCFDEQ35606471-A0BA8FED-49D9-4200-B5A2-90B07824F7D1Q35824476-F77CDA36-E5B0-4EB6-9350-9E2257D29B78Q36157166-93BB989F-CE79-4E4C-98C5-9B8AD71DFE79Q36529423-956A56EA-18F1-4F02-B915-C9157EA2D44CQ36796675-64645365-4676-4EE7-BB71-0282133985C2Q36813049-1E982753-E10C-476C-BB94-CA1F61F318B7Q36850160-2F6110E7-2F06-4A70-850E-D12FB418C5A5Q36872219-DB483FBC-BB35-45AB-944D-EE463A9832B2Q36990708-8F908F26-94F6-4763-AE81-DC096D6AB3BEQ37176694-C55F687A-6C0E-434A-A8F7-A01E30A0F1BEQ37240139-EA5F019B-C576-476F-8781-BBF054EAAB9AQ37636030-84F6429D-94C4-4405-BDD3-948EE90D0E1BQ37734230-F3B4E3BB-C861-4D76-AA55-6D43DD2F20BBQ38495604-84B34E2D-DA24-4720-9DA5-207FF0BF16E5Q40085912-75ED5DE9-3492-46F3-AA67-B4EC17667E89Q41680809-D9BAB4D7-355A-4555-BC8E-9D5383CD28F3Q42467296-00C1F262-8C71-4DD3-852B-EE11C8DDBA70
P2860
Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia
description
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1997
@ast
im Juli 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1997/07/01)
@sk
vědecký článek publikovaný v roce 1997
@cs
wetenschappelijk artikel (gepubliceerd op 1997/07/01)
@nl
наукова стаття, опублікована в липні 1997
@uk
مقالة علمية (نشرت في يوليو 1997)
@ar
name
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@ast
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@en
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@nl
type
label
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@ast
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@en
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@nl
prefLabel
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@ast
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@en
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@nl
P2093
P921
P1433
P1476
Antiproliferative role of dopa ...... tion and pituitary hyperplasia
@en
P2093
A. Saiardi
E. Borrelli
J. H. Baik
P304
P356
10.1016/S0896-6273(00)80352-9
P407
P577
1997-07-01T00:00:00Z